Reuters: Regulatory News: Rigel drops asthma drug after mid-stage study fails

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

The Best Way to Manage your Money. Start using Mint today to set a budget, track your goals and do more with your money. From our sponsors

Rigel drops asthma drug after mid-stage study fails Aug 26th 2013, 11:47 Mon Aug 26, 2013 7:47am EDT Aug 26 (Reuters) - Rigel Pharmaceuticals Inc said it will stop developing its experimental asthma drug after the therapy failed to improve the lung function of patients in a mid-stage trial. The inhaled drug, R343, was being tested as a treatment for patients with allergic asthma. While the drug was shown to be relatively safe and well tolerated, the trial failed to meet any of its goals, Rigel said. The company said it will review its drug pipeline and will discuss its plans in the 'near-term.'

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions